vs
BANK OF HAWAII CORP（BOH）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
BANK OF HAWAII CORP的季度营收约是再鼎医药的1.5倍（$192.3M vs $127.1M），过去两年再鼎医药的营收复合增速更高（20.8% vs 10.7%）
夏威夷银行是美国夏威夷州的区域性商业银行，总部位于檀香山，是夏威夷第二古老的银行，也是当地最大的本土银行，多数表决权股东均居住在州内。该行的账户数、客户规模、营业网点及ATM数量均居夏威夷金融机构首位，业务涵盖零售银行、商业银行、投资服务、资金运营四大板块。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
BOH vs ZLAB — 直观对比
营收规模更大
BOH
是对方的1.5倍
$127.1M
两年增速更快
ZLAB
近两年复合增速
10.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $192.3M | $127.1M |
| 净利润 | $57.4M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 29.9% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | 30.6% | — |
| 每股收益（稀释后） | $1.30 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BOHZLAB
| Q1 26 | $192.3M | — | ||
| Q4 25 | $189.6M | $127.1M | ||
| Q3 25 | $182.6M | $115.4M | ||
| Q2 25 | $174.5M | $109.1M | ||
| Q1 25 | $169.9M | $105.7M | ||
| Q4 24 | $163.2M | $108.5M | ||
| Q3 24 | $162.7M | $101.8M | ||
| Q2 24 | $156.9M | $100.1M |
净利润BOHZLAB
| Q1 26 | $57.4M | — | ||
| Q4 25 | $60.9M | — | ||
| Q3 25 | $53.3M | $-36.0M | ||
| Q2 25 | $47.6M | $-40.7M | ||
| Q1 25 | $44.0M | $-48.4M | ||
| Q4 24 | $39.2M | — | ||
| Q3 24 | $40.4M | $-41.7M | ||
| Q2 24 | $34.1M | $-80.3M |
毛利率BOHZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率BOHZLAB
| Q1 26 | — | — | ||
| Q4 25 | 40.9% | -54.6% | ||
| Q3 25 | 37.1% | -42.3% | ||
| Q2 25 | 34.6% | -50.3% | ||
| Q1 25 | 33.1% | -53.3% | ||
| Q4 24 | 31.6% | -62.6% | ||
| Q3 24 | 32.3% | -66.6% | ||
| Q2 24 | 28.9% | -76.0% |
净利率BOHZLAB
| Q1 26 | 29.9% | — | ||
| Q4 25 | 32.1% | — | ||
| Q3 25 | 29.2% | -31.2% | ||
| Q2 25 | 27.3% | -37.3% | ||
| Q1 25 | 25.9% | -45.8% | ||
| Q4 24 | 24.0% | — | ||
| Q3 24 | 24.8% | -40.9% | ||
| Q2 24 | 21.7% | -80.2% |
每股收益（稀释后）BOHZLAB
| Q1 26 | $1.30 | — | ||
| Q4 25 | $1.40 | $-0.05 | ||
| Q3 25 | $1.20 | $-0.03 | ||
| Q2 25 | $1.06 | $-0.04 | ||
| Q1 25 | $0.97 | $-0.04 | ||
| Q4 24 | $0.85 | $-0.09 | ||
| Q3 24 | $0.93 | $-0.04 | ||
| Q2 24 | $0.81 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.3M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $715.5M |
| 总资产 | $23.9B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BOHZLAB
| Q1 26 | $3.3M | — | ||
| Q4 25 | $946.5M | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | $935.2M | $757.3M | ||
| Q4 24 | $763.6M | $779.7M | ||
| Q3 24 | $1.3B | $616.1M | ||
| Q2 24 | $925.3M | $630.0M |
总债务BOHZLAB
| Q1 26 | — | — | ||
| Q4 25 | $558.2M | — | ||
| Q3 25 | $558.2M | — | ||
| Q2 25 | $558.2M | — | ||
| Q1 25 | $558.3M | — | ||
| Q4 24 | $558.3M | — | ||
| Q3 24 | $558.3M | — | ||
| Q2 24 | $560.1M | — |
股东权益BOHZLAB
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.9B | $715.5M | ||
| Q3 25 | $1.8B | $759.9M | ||
| Q2 25 | $1.7B | $791.7M | ||
| Q1 25 | $1.7B | $810.8M | ||
| Q4 24 | $1.7B | $840.9M | ||
| Q3 24 | $1.7B | $667.7M | ||
| Q2 24 | $1.6B | $704.2M |
总资产BOHZLAB
| Q1 26 | $23.9B | — | ||
| Q4 25 | $24.2B | $1.2B | ||
| Q3 25 | $24.0B | $1.2B | ||
| Q2 25 | $23.7B | $1.2B | ||
| Q1 25 | $23.9B | $1.2B | ||
| Q4 24 | $23.6B | $1.2B | ||
| Q3 24 | $23.8B | $985.3M | ||
| Q2 24 | $23.3B | $987.4M |
负债/权益比BOHZLAB
| Q1 26 | — | — | ||
| Q4 25 | 0.30× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | 0.33× | — | ||
| Q4 24 | 0.33× | — | ||
| Q3 24 | 0.34× | — | ||
| Q2 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流BOHZLAB
| Q1 26 | — | — | ||
| Q4 25 | $218.3M | $-26.0M | ||
| Q3 25 | $38.5M | $-32.0M | ||
| Q2 25 | $81.7M | $-31.0M | ||
| Q1 25 | $18.3M | $-61.7M | ||
| Q4 24 | $170.9M | $-55.8M | ||
| Q3 24 | $-20.3M | $-26.8M | ||
| Q2 24 | $45.7M | $-42.2M |
自由现金流BOHZLAB
| Q1 26 | — | — | ||
| Q4 25 | $184.3M | $-26.7M | ||
| Q3 25 | $29.8M | $-35.0M | ||
| Q2 25 | $72.6M | $-33.9M | ||
| Q1 25 | $10.2M | $-63.2M | ||
| Q4 24 | $161.3M | $-58.4M | ||
| Q3 24 | $-25.0M | $-28.2M | ||
| Q2 24 | $40.7M | $-42.9M |
自由现金流率BOHZLAB
| Q1 26 | — | — | ||
| Q4 25 | 97.2% | -21.0% | ||
| Q3 25 | 16.3% | -30.4% | ||
| Q2 25 | 41.6% | -31.1% | ||
| Q1 25 | 6.0% | -59.9% | ||
| Q4 24 | 98.8% | -53.8% | ||
| Q3 24 | -15.3% | -27.7% | ||
| Q2 24 | 26.0% | -42.9% |
资本支出强度BOHZLAB
| Q1 26 | — | — | ||
| Q4 25 | 18.0% | 0.5% | ||
| Q3 25 | 4.7% | 2.6% | ||
| Q2 25 | 5.2% | 2.6% | ||
| Q1 25 | 4.8% | 1.5% | ||
| Q4 24 | 5.9% | 2.4% | ||
| Q3 24 | 2.8% | 1.3% | ||
| Q2 24 | 3.2% | 0.7% |
现金转化率BOHZLAB
| Q1 26 | — | — | ||
| Q4 25 | 3.58× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 1.71× | — | ||
| Q1 25 | 0.42× | — | ||
| Q4 24 | 4.36× | — | ||
| Q3 24 | -0.50× | — | ||
| Q2 24 | 1.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BOH
| Net Interest Income | $151.0M | 79% |
| Noninterest Income | $41.3M | 21% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
